Akebia Therapeutics, Inc. total revenue, net income and dynamics of changes in US dollar today
Net revenue Akebia Therapeutics, Inc. is now 52 304 000 $. Information about net revenue is taken from open sources. Net income of Akebia Therapeutics, Inc. today amounted to -69 580 000 $. These are the main financial indicators of Akebia Therapeutics, Inc.. Akebia Therapeutics, Inc. online financial report chart. The financial report chart shows the values from 30/06/2017 to 31/03/2021. All information on Akebia Therapeutics, Inc. total revenue on this chart is created in the form of yellow bars.
Report date
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
and
Change (%)
Comparing current quartal report this year to quartal report last year.
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
and
Change (%)
Comparing current quartal report this year to quartal report last year.
31/03/2021
52 304 000 $
-28.0214 % ↓
-69 580 000 $
-
31/12/2020
56 699 000 $
-5.265 % ↓
-87 000 000 $
-
30/09/2020
59 988 000 $
-34.779 % ↓
-59 959 000 $
-
30/06/2020
90 142 000 $
-10.576 % ↓
-175 751 000 $
-
30/09/2019
91 977 000 $
-
-54 585 000 $
-
30/06/2019
100 803 000 $
-
-58 170 000 $
-
31/03/2019
72 666 000 $
-
-72 421 000 $
-
31/12/2018
59 850 000 $
-
-60 054 000 $
-
30/09/2018
53 169 000 $
-
-26 047 000 $
-
30/06/2018
48 793 000 $
-
-34 069 000 $
-
31/03/2018
45 930 000 $
-
-23 418 000 $
-
31/12/2017
87 316 000 $
-
12 280 000 $
-
30/09/2017
41 283 000 $
-
-23 134 000 $
-
30/06/2017
28 520 000 $
-
-21 518 000 $
-
Show:
to
Akebia Therapeutics, Inc. financial report charts
The latest dates of Akebia Therapeutics, Inc. financial statements available online: 30/06/2017, 31/12/2020, 31/03/2021. The dates of the financial statements are determined by the accounting rules. The current date of the financial report of Akebia Therapeutics, Inc. for today is 31/03/2021. Gross profit Akebia Therapeutics, Inc. is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services. Gross profit Akebia Therapeutics, Inc. is 6 978 000 $
Akebia Therapeutics, Inc. quarterly report dates
Cost of revenue Akebia Therapeutics, Inc. is the total cost of producing and distributing of products and services of a company. Cost of revenue Akebia Therapeutics, Inc. is 45 326 000 $ Total revenue Akebia Therapeutics, Inc. refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods. Total revenue Akebia Therapeutics, Inc. is 52 304 000 $ Operating income Akebia Therapeutics, Inc. is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS). Operating income Akebia Therapeutics, Inc. is -43 361 000 $
Net income Akebia Therapeutics, Inc. is an entity's income minus cost of goods sold, expenses and taxes for an accounting period. Net income Akebia Therapeutics, Inc. is -69 580 000 $ Current assets Akebia Therapeutics, Inc. is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year. Current assets Akebia Therapeutics, Inc. is 365 017 000 $ Total assets Akebia Therapeutics, Inc. refers to the total amount of assets owned by a person or entity. Total assets Akebia Therapeutics, Inc. is 628 703 000 $
31/03/2021
31/12/2020
30/09/2020
30/06/2020
30/09/2019
30/06/2019
31/03/2019
31/12/2018
30/09/2018
30/06/2018
31/03/2018
31/12/2017
30/09/2017
30/06/2017
Gross profit
Gross profit is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services.
6 978 000 $
-7 702 000 $
5 082 000 $
16 091 000 $
82 786 000 $
5 945 000 $
-17 992 000 $
-28 749 000 $
-17 465 000 $
-23 124 000 $
-
-
-
-
Cost of revenue
Cost of revenue is the total cost of producing and distributing of products and services of a company.
45 326 000 $
64 401 000 $
54 906 000 $
74 051 000 $
9 191 000 $
94 858 000 $
90 658 000 $
88 599 000 $
70 634 000 $
71 917 000 $
-
-
-
-
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
52 304 000 $
56 699 000 $
59 988 000 $
90 142 000 $
91 977 000 $
100 803 000 $
72 666 000 $
59 850 000 $
53 169 000 $
48 793 000 $
45 930 000 $
87 316 000 $
41 283 000 $
28 520 000 $
Operating revenue
Operating revenue is revenue generated from a company's primary business activities. For example, a retailer produces revenue through merchandise sales, and a physician derives revenue from the medical services he/she provides.
-
-
-
-
91 977 000 $
100 803 000 $
72 666 000 $
59 850 000 $
53 169 000 $
48 793 000 $
45 930 000 $
87 316 000 $
41 283 000 $
28 520 000 $
Operating income
Operating income is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS).
-43 361 000 $
-55 221 000 $
-41 195 000 $
-28 492 000 $
-35 005 000 $
-39 223 000 $
-61 383 000 $
-62 287 000 $
-27 843 000 $
-35 662 000 $
-24 498 000 $
11 367 000 $
-24 176 000 $
-22 136 000 $
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
-69 580 000 $
-87 000 000 $
-59 959 000 $
-175 751 000 $
-54 585 000 $
-58 170 000 $
-72 421 000 $
-60 054 000 $
-26 047 000 $
-34 069 000 $
-23 418 000 $
12 280 000 $
-23 134 000 $
-21 518 000 $
R&D spending
Research and Development spending - cost of investigative activities to improve existing products and procedures or to lead to the development of new products and procedures.
-
-
-
-
74 512 000 $
85 694 000 $
85 694 000 $
85 694 000 $
-
-
61 404 000 $
68 382 000 $
58 711 000 $
43 751 000 $
Operating expense
An operating expense is an expenditure that a business incurs as a result of performing its normal business operations.
95 665 000 $
111 920 000 $
101 183 000 $
118 634 000 $
126 982 000 $
140 026 000 $
134 049 000 $
122 137 000 $
81 012 000 $
84 455 000 $
70 428 000 $
75 949 000 $
65 459 000 $
50 656 000 $
Current assets
Current assets is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year.
365 017 000 $
371 437 000 $
391 000 000 $
449 102 000 $
299 008 000 $
316 396 000 $
347 233 000 $
468 275 000 $
397 526 000 $
407 417 000 $
436 981 000 $
358 356 000 $
333 938 000 $
332 389 000 $
Total assets
Total assets refers to the total amount of assets owned by a person or entity.
628 703 000 $
644 139 000 $
676 143 000 $
745 174 000 $
795 220 000 $
823 528 000 $
890 793 000 $
996 540 000 $
403 826 000 $
413 781 000 $
442 713 000 $
364 247 000 $
338 589 000 $
336 822 000 $
Current cash
Current cash - the sum of all of the cash a company has on the date of report.
252 765 000 $
228 698 000 $
169 286 000 $
245 406 000 $
122 886 000 $
87 212 000 $
62 741 000 $
104 644 000 $
162 430 000 $
163 526 000 $
159 452 000 $
70 156 000 $
89 599 000 $
125 390 000 $
Current debt
Current debt is the portion of debt due within a year (12 months) and is listed as a current liability and part of net working capital.
-
-
-
-
223 148 000 $
185 618 000 $
202 613 000 $
265 693 000 $
177 399 000 $
164 420 000 $
-
-
-
-
Total cash
Total cash - the sum of all of the cash a company has on its books, including petty cash and funds on deposit in a bank.
-
-
-
-
-
-
-
-
-
-
393 029 000 $
317 792 000 $
329 705 000 $
321 215 000 $
Total debt
Total debt is a combination of both short-term and long-term debt. Short-term debts are those that must be paid back within a year. Long-term debt generally includes every liability that must be paid off in more than a year.
-
-
-
-
327 658 000 $
304 172 000 $
324 414 000 $
360 612 000 $
261 285 000 $
247 857 000 $
-
-
-
-
Debt ratio
Total debt to total assets - is a financial ratio that indicates the percentage of a company's assets that are provided via debt.
-
-
-
-
41.20 %
36.94 %
36.42 %
36.19 %
64.70 %
59.90 %
-
-
-
-
Shareholders equity
Shareholder's equity (SE) is the owner's claim after subtracting total liabilities from total assets.
213 891 000 $
247 618 000 $
317 962 000 $
370 260 000 $
467 562 000 $
519 356 000 $
566 379 000 $
635 928 000 $
142 541 000 $
165 924 000 $
197 097 000 $
119 331 000 $
99 875 000 $
56 998 000 $
Cash flow
Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business.
-
-
-
-
10 989 000 $
-38 366 000 $
-137 929 000 $
-73 699 000 $
-12 461 000 $
8 996 000 $
-20 330 000 $
-16 378 000 $
-54 617 000 $
24 364 000 $
Last revenue report of Akebia Therapeutics, Inc. was 31/03/2021. According to last financial report total revenue in Akebia Therapeutics, Inc. was 52 304 000 US dollar and changed by -28.0214% since last year. Net income in Akebia Therapeutics, Inc. was -69 580 000 $ in last quartal, net income changes to 0%.
Current cash Akebia Therapeutics, Inc. - the sum of all of the cash a company has on the date of report. Current cash Akebia Therapeutics, Inc. is 252 765 000 $
Akebia Therapeutics, Inc. stocks data
AKBA stock price
Akebia Therapeutics, Inc. stock price today, AKBA stock quote.
